|
Variable
|
ADRs of MTX (N = 398)
|
|---|
|
Yes
|
No
|
ρ*
|
|---|
|
n = 252
|
n = 146
| |
|---|
|
Sex (%)
|
|
Female
|
174 (63.3)
|
101 (36.7)
|
0.978
|
|
Male
|
78 (63.4)
|
45 (36.6)
| |
|
Age (years) – Cohort in median
|
|
≤ 16
|
236 (72.6)
|
89 (27.4)
|
< 0.001
|
|
> 16
|
16 (21.9)
|
57 (78.1)
| |
|
Route of administration of MTX (%)
|
|
Subcutaneous
|
40 (62.5)
|
24 (37.5)
|
0.882
|
|
Oral
|
212 (63.5)
|
122 (36.5)
| |
|
Dose of MTX (mg/kg/week)
|
|
≥ 0.6
|
175 (69.7)
|
76 (30.3)
|
0.001
|
|
< 0.6
|
77 (52.4)
|
70 (47.6)
| |
|
Disease (%)
|
|
JIA
|
207 (68.1)
|
97 (31.9)
|
0.001
|
|
JSLE
|
20 (57.1)
|
15 (42.9)
| |
|
JDM
|
25 (42.4)
|
34 (57.6)
| |
- N - number of patients treated with MTX, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis
- * Chi Pearson square or Fisher’s exact. P < 0.05
